Press Releases Vericel Corporation

Equities

VCEL

US92346J1088

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
48.35 ^USD	+1.55%		+0.52%	+35.78%

May. 08	Vericel Q1 Loss Narrows, Revenue Increases; 2024 Outlook Lifted -- Shares Rise Pre-Bell	MT
May. 08	Earnings Flash (VCEL) VERICEL CORPORATION Posts Q1 Revenue $51.3M, vs. Street Est of $49.1M	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance	May. 08	GL
Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024	Apr. 24	GL
Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance	Feb. 29	GL
Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance	Feb. 29	AQ
Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024	Feb. 27	GL
Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024	Feb. 27	AQ
Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024	Feb. 15	GL
Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024	Feb. 15	AQ
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024	Feb. 05	GL
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results	Jan. 09	GL
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results	Jan. 09	AQ
Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024	Jan. 03	GL
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army	Dec. 29	AQ
Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance	Nov. 08	GL
Vericel to Present at the Stephens Annual Investment Conference	Nov. 07	GL
Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023	23-10-25	GL
Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid	23-09-28	GL
Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults	23-09-20	GL
Vericel to Present at the Morgan Stanley Global Healthcare Conference	23-09-06	GL
Vericel : Q2 2023 Earnings Presentation	23-08-02	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Vericel Corporation

Equities

VCEL

US92346J1088

Press Releases

Filters